




GHIT R&D Forum

December 8th, 2017

Tokyo Garden Terrace Kioi Conference



GHIT Fund

Global Health Innovative Technology Fund

GHIT R&D Forum

Date & Time: Friday December 8th, 2017 9:00 - 17:20 (Followed by reception)

Venue: Tokyo Garden Terrace Kioi Conference

Language: English

Sponsor: Japan Association for International Health, Japanese Society of Parasitology, Japanese Society of Tropical Medicine, Japan Pharmaceutical Manufacturers Association

Program

8:00 - 9:00	Registration & Networking Breakfast
9:00 - 9:10	Greetings and Opening Remarks Kiyoshi Kurokawa, MD Professor Emeritus, National Graduate Institute for Policy Studies Chairman, Health and Global Policy Institute Representative Director and Chair, GHIT Fund
9:10 - 9:15	Brief presentation on 'ConnexMe'
9:15 - 10:25	Session 1: Activating the Power of Japan's Unique Chemical Compounds for Neglected Diseases Screening/HTLP Projects
9:15 - 9:25	<i>Partnering with Japanese Pharma to Combat Neglected Diseases</i> Peter Warner, PhD Senior Program Officer, Discovery and Translational Sciences Bill & Melinda Gates Foundation
9:25 - 9:35	<i>New anti-malarial drug discovery projects with Japanese Partners</i> Paul Willis, PhD Senior Director, Drug Discovery Medicines for Malaria Venture (MMV)
9:35 - 9:45	<i>Daiichi Sankyo's challenges for Malaria, TB and NTDs with GHIT Fund</i> Tsuyoshi Watanabe, PhD Associate Director, Research Planning Daiichi Sankyo Co., Ltd.
9:45 - 9:55	<i>The NTD Drug Discovery Booster: an innovative collaboration for hit expansion</i> Charles Mowbray, PhD FRSC Discovery Director Drugs for Neglected Diseases initiative (DNDi)
9:55 - 10:05	<i>TB Alliance Screening Projects with GHIT With an Emphasis on Natural Products</i> Takushi Kaneko, PhD Senior Research Fellow, Discovery Group Global Alliance for TB Drug Development (TB Alliance)
10:05 - 10:25	Q&A - Moderator: Kei Katsuno (Senior Director, Investment Strategy & Government Relations, GHIT Fund)
10:25 - 10:40	Coffee Break
10:40 - 11:40	Session 2: Trailblazing Novel Technologies: Harnessing Japanese Know-How for Early-Stage Innovation
10:40 - 10:50	<i>Wellcome Trust & GHIT A New Partnership</i> Ann Mills-Duggan, PhD Head, Seeding Drug Discovery Fund, Business Development, Innovations Wellcome Trust
10:50 - 11:00	<i>A Vaccine to Block Malaria Transmission: Pfs230 Antigen Design and Display (T2016-207)</i> Takafumi Tsuboi, MD, PhD Director, Proteo-Science Center Ehime University
11:00 - 11:10	<i>Development of serological biomarkers as indicators of recent and asymptomatic infections for innovative tools to accelerate malaria elimination</i> Matthias Harbers, PhD Vice President, Sales & Marketing Division CellFree Sciences Co., Ltd. Visiting Scientist, Division of Genomic Technologies RIKEN Center for Life Science Technologies (CLST)
11:10 - 11:20	<i>T2016-101 Host-directed drug targeting against tuberculosis</i> Harukazu Suzuki, PhD Group Director, Division of Genomic Technologies RIKEN Center for Life Science Technologies (CLST)
11:20 - 11:40	Q&A - Moderator: Hayato Urabe (Director, Investment Strategy, Planning & Management, GHIT Fund)

11:40 - 13:00	Lunch Break
13:00 - 14:00	Session 3: Catapulting Translational Development through Global Partnerships
13:00 - 13:10	<i>Preclinical development of an anti-Dengue virus antibody that neutralizes all four serotypes</i> Hisafumi Okabe, PhD Senior Vice President, Officer in charge of Research, Translational Clinical Research Chugai Pharmaceutical Co., Ltd.
13:10 - 13:20	<i>Highly Sensitive POC TB-LAM Rapid Diagnostic Test</i> Takeshi Yamamoto, PhD Senior Manager, Pharmaceutical & Healthcare Research Laboratories Fujifilm Corporation
13:20 - 13:30	<i>Automatic Malaria Diagnostic Device</i> Tatsuo Mizuno Executive Director and Secretary General Malaria No More Japan
13:30 - 13:40	<i>To combat 21st century global public health problems, we develop next generation vaccines against Infectious diseases and Cancer</i> Wataru Akahata, PhD Founder & Chief Executive Officer VLP Therapeutics
13:40 - 14:00	Q&A - Moderator: Kei Katsuno (Senior Director, Investment Strategy & Government Relations, GHIT Fund)
14:05 - 14:55	Session 4 Part I: Propelling R&D for Late-Stage Projects
14:05 - 14:15	<i>Clinical Development of BK-SE36/CpG Malaria Vaccine: Safety evaluation of BK-SE36/CpG in the malaria endemic population</i> Toshihiro Horii, PhD Professor, Department of Molecular Protozoology, Research Institute for Microbial Diseases Osaka University
14:15 - 14:25	<i>GHIT, Takeda and MMV collaboration: Advancing DSM265 from candidate selection to phase IIa</i> Jörg Möhrle, PhD VP Head of Translational Medicine Medicines for Malaria Venture (MMV)
14:25 - 14:35	<i>Inactivated Mycobacterium obuense A whole cell non-tuberculous mycobacterial vaccine booster SRL172 (broth) DAR-901 (agar)</i> C. Fordham von Reyn, MD Professor of Medicine, Infectious Disease and International Health Director, DarDar International Program at Geisel School of Medicine at Dartmouth
14:35 - 14:55	Q&A - Moderator: Hayato Urabe (Director, Investment Strategy, Planning & Management, GHIT Fund)
14:55 - 15:10	Coffee Break
15:10 - 16:00	Session 4 Part II: Propelling R&D for Late-Stage Projects
15:10 - 15:20	<i>The Pediatric Praziquantel Consortium Helping children with Schistosomiasis</i> Remco de Vruet, PhD Program Manager Lygature
15:20 - 15:30	<i>Clinical Development of E1224 "A New Treatment for Chagas Disease" & "Mycetoma Treatment, Fosravuconazole Clinical Trial"</i> Daisuke Imoto Head of Office Drugs for Neglected Diseases initiative (DNDi) Japan
15:30 - 15:40	<i>"A new treatment for Chagas disease" and "Mycetoma Treatment, Fosravuconazole Clinical Trial"</i> Katsura Hata, D.V.M, PhD Senior Director, Global Health Research Section, hhc Data Creation Center Eisai Co., Ltd.
15:40 - 16:00	Q&A - Moderator: Hayato Urabe (Director, Investment Strategy, Planning & Management, GHIT Fund)
16:00 - 16:15	Break
16:15 - 17:05	Session 5: Joining Forces for Product Delivery Preparedness
16:15 - 16:25	<i>Japan Agency for Research and Development (AMED); Its Missions and Challenges</i> Masahiko Noda Managing Director, Department of International Affairs Japan Agency for Medical Research and Development (AMED)

16:25 - 16:35	<i>European & Developing Countries Clinical Trials Partnership (EDCTP)</i> Ole F. Olesen Director, North-North Cooperation European & Developing Countries Clinical Trials Partnership (EDCTP)
16:35 - 16:45	<i>About UNITAID</i> Sanne Fournier-Wendes Senior Adviser to the Executive Director Executive Office, UNITAID
16:45 - 17:05	Q&A - Moderator: Kei Katsuno (Senior Director, Investment Strategy & Government Relations, GHIT Fund)
17:10 - 17:20	Closing Remarks BT Slingsby, MD, PhD, MPH CEO GHIT Fund
17:30 - 19:30	Reception

Please note: The details of the program may be subject to change.



GHIT R&D Forum

Date & Time: December 8th, 2017 9:00 - 17:30

Venue: Tokyo Garden Terrace Kioi Conference

Greetings and Opening Remarks



Kiyoshi Kurokawa, MD

Professor Emeritus,
National Graduate Institute for Policy Studies
Chairman, Health and Global Policy Institute

A graduate of University of Tokyo Faculty of Medicine, Dr. Kurokawa was a professor of medicine in the School of Medicine at UCLA (1979-84) and at the University of Tokyo (1989-96). He also served as Dean of Tokai University School of Medicine (1996-2002), President of Science Council of Japan (2003-06), Science Advisor to the Prime Minister (2006-08), and WHO Commissioner (2005-09). He is currently an executive member of many national and international professional societies.

His website: www.kiyoshikurokawa.com/en

Session 1: Activating the Power of Japan's Unique Chemical Compounds for Neglected Diseases



Peter Warner, PhD

Senior Program Officer in
Discovery and Translational Sciences
Bill and Melinda Gates Foundation (BMGF)

Dr Peter Warner joined the Bill and Melinda Gates Foundation (BMGF) in 2013 after a 28-year career in the Pharma industry. Trained as a medicinal chemist, he has worked across a broad range of disease areas delivering drug candidates to the clinic working in senior research management positions in UK, Sweden and India. Immediately prior to joining the BMGF in Seattle, USA he was Vice President and head of the AstraZeneca Neglected Diseases Research Unit in Bangalore. Within the BMGF he manages a portfolio of drug discovery grants focused primarily on tuberculosis, malaria and filarial diseases and is the co-leader of the TB Drug Accelerator consortium. He currently chairs the GHIT Hit-to-lead Platform (HTLP) expert panel.



Paul Willis, PhD

Senior Director, Drug Discovery
Medicines for Malaria Venture (MMV)

Paul Willis is a Medicinal Chemist and Senior Director of Drug Discovery at Medicines for Malaria Venture where he provides drug discovery advice to a portfolio of antimalarial drug discovery projects. Paul also oversees many of the MMV Open science projects. He was previously employed as a team leader and project leader at AstraZeneca, working on cardiovascular, respiratory and anti-inflammatory drug discovery projects which delivered two marketed drugs.



Tsuyoshi Watanabe, PhD

Associate Director of Research Planning
Daiichi Sankyo CO., LTD.

Tsuyoshi Watanabe, Ph.D. is an associate director of research planning at Daiichi Sankyo CO., LTD. He (born in Sapporo, Japan, in Oct. 1971) received B.S. and M.S. degrees in organic chemistry from Nagoya University, Japan, in 1994 and 1996, respectively. He received a Ph.D. in organic chemistry from Nagoya University supervised by Prof. Hisashi Yamamoto, in 1999. He was a Post-doctoral fellow at Universitat Basel at Prof. Bernd Giese group (1999-2000). His research interests included medicinal chemistry and development of new synthetic methodology. He joined legacy Sankyo CO., LTD. in 2000 as a medicinal chemist and worked on diabetes, cardiovascular, antifungal projects. He changed his



Takushi Kaneko, PhD

Senior Research Fellow
TB Alliance

Dr. Takushi Kaneko is a Senior Research Fellow at TB Alliance where he is responsible for overseeing drug discovery research activities between the TB Alliance and collaborating pharmaceutical companies and academic institutions. Before joining TB Alliance, he was a Research Fellow in the Antibacterial Drug Discovery Group at Pfizer Global Research and Development Division in Groton, CT. He also managed the Natural Product Discovery Team in Pfizer in Groton. Prior to Pfizer, Dr. Kaneko worked in the Oncology Drug Discovery Group in Bristol-Myers Pharmaceutical Research and Development Division in Wallingford, CT. He is a graduate of the University of Michigan where he earned his M.S. and Ph.D. degrees

carrier to a research strategy department to work on alliance activity including an in-licensing activity of CS-3150 and several other early stage collaborations. After the merger of legacy Daiichi Pharmaceutical and legacy Sankyo CO., LTD., he had been assigned as an associate director at research planning group and worked on research collaboration with companies, design of an open innovation framework and research on NTDs supported by GHIT Fund.



Charles Mowbray, PhD FRSC
Discovery Director
Drugs for Neglected Diseases *initiative* (DNDi)

Dr Mowbray joined DNDi in August 2011 as Head of Drug Discovery with responsibility for lead optimization in drug discovery projects. Prior to joining DNDi, Dr Mowbray spent 19 years at Pfizer Worldwide Research and Development where he was most recently a Research Fellow in Worldwide Medicinal Chemistry at the Sandwich Laboratories, UK. During this time he developed experience as a medicinal chemist, project leader and people manager. He has delivered projects across many disease areas, target classes and medicinal chemistry strategies and from target selection through to clinical candidate delivery. Five of these molecules have entered Phase I and two have completed Phase IIb clinical studies. Dr. Mowbray is an author of 28 scientific publications and an inventor on 15 patents. Dr. Mowbray was promoted to the role of Discovery Director in April 2017 with responsibility for overseeing all of DNDi's Discovery activities. Dr Mowbray was awarded his PhD by the University of Exeter and completed postdoctoral fellowships at the University of British Columbia and the University of Nottingham.

under Professor J. P. Marino. He later carried out postdoctoral research at Harvard University with Professor Y. Kishi. Dr. Kaneko is an author of more than 70 scientific publications.

Session 2: Trailblazing Novel Technologies: Harnessing Japanese Know-How for Early-Stage Innovation




Takafumi Tsuboi, MD, PhD
Director, Proteo-Science Center
Ehime University

Dr. Takafumi Tsuboi is the Director of Proteo-Science Center (PROS) at Ehime University, Japan and Professor at the Division of Malaria Research, PROS. PROS has established the eukaryotic wheat germ cell-free protein synthesis system (WGCFs) for translational research especially for development of medical application. Recent advances on bioinformatics and genome database of malaria parasites has accelerated the usefulness of the WGCFs to screen for many malaria parasite proteins in short time. His laboratory is a pioneer to use this system for production of malaria proteins, for example, it can produce 2000~ malaria proteins. Based on the accumulated results to date, WGCFs successfully produces correct conformation of the malaria proteins, which are difficult to be done in any other systems. Major research interests of Dr. Tsuboi's group are as follows: 1) Genome-wide discovery of novel malaria vaccine candidates, 2) Malaria transmission-blocking vaccine research, 3) Understanding of molecular mechanism of malaria parasite invasion into host cell. Currently Dr. Tsuboi's team at PROS, Ehime University is partnering with PATH's Malaria Vaccine Initiative (MVI) on malaria transmission-blocking vaccine research supported by GHIT Fund.



Harukazu Suzuki, PhD
RIKEN Center for Life Science Technologies

Dr. Harukazu Suzuki is interested in how molecules promote function of cells in mammals. He first encountered cDNA cloning technology when he was a PhD student, which was the beginning of his career as a researcher. Dr. Suzuki and his team have revealed primary structure of voltage-dependent sodium channels by using the cDNA technology, and investigated structure-function relationship in combination with the channel mutant synthesis and the electro-physical measurement (patch clamping) where he had the opportunity to study in Germany. After getting his PhD, he worked several years in a pharmaceutical company in Japan in which he learned that basic science is very important for drug development. Then, he joined the full-length cDNA collection project (early FANTOM1 to 3) in



Matthias Harbers, PhD
Vice President, CellFree Sciences Co., Ltd.
Visiting Scientist, RIKEN Center for
Life Science Technologies

Dr. Matthias Harbers is a Vice President of CellFree Sciences, and holds a position as a Visiting Scientist to the RIKEN Center for Life Science Technologies. He has over 25 years of experience doing business and technology development in the Japanese biotech industry and having worked at renown international research institutions. In his current responsibility, he manages international business relationships including projects for utilizing cell-free protein expression in malaria and infectious disease research. Previously, he had contributed to large-scale cDNA cloning and genome analysis projects. Before coming to Japan, had worked at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg, France, and the Karolinska Institute in Stockholm, Sweden. He graduated from the Faculty of Chemistry at the University of Hamburg in Germany, where he also obtained his PhD for studies on tumor promotion and cell signaling.



Ann Mills-Duggan, PhD
Head, Seeding Drug Discovery Fund,
Business Development, Innovations
Wellcome Trust

Dr. Ann Mills-Duggan joined the Wellcome Trust in 2010 where she is currently responsible for establishing and managing partnerships between Wellcome and the pharmaceutical industry. Previously Ann headed the £200M Wellcome Trust Seeding Drug Discovery Fund which supported small molecule drug discovery and development programs worldwide. Prior to joining the Trust Dr Mills-Duggan spent over twenty years in the pharmaceutical industry, most recently with UCB and previously with GlaxoSmithKline and GlaxoWellcome, working in research, licensing, alliance management and life science investing. Ann is a graduate of the University of Bath, UK and earned her PhD at Imperial College, London. In addition to being a member of the GHIT Selection Committee Dr Mills-

RIKEN to answer a quite simple question: How many genes there are in mammals. At that time mammalian genome sequence was not available. Now everyone knows mammals consist of approximately 20,000 genes, which is comparable to fly and worm and was far smaller than previously estimated/expected (100,000). Disappointed, but at the same time, he was particularly interested in how mammals critically regulate expression of such small number of genes in their entire complicated life, which was his motivation to join the current FANTOM projects (FANTOM4-6). He met Professor Frank Brombacher, a partner researcher of the GHIT grant, in the FANTOM3 and started the collaboration research in 2010. They focus on transcriptional regulation of macrophage activations, and protective and subversive mechanisms of macrophage genes in tuberculosis infection, which is based on the GHIT grant proposal. Science is endless; once we solve a question then next question comes, which is a great fun to Dr. Suzuki.

Duggan is also involved with a number of strategic groups outside Wellcome including the Steering Board of the UK's HealthTech and Medicines Knowledge Transfer Network and the British Heart Foundation's Translational Advisory Group.

Session 3: Catapulting Translational Development through Global Partnerships



Hisafumi Okabe, PhD

Senior Vice President, Officer in charge of Research,
Translational Clinical Research,
Chugai Pharmaceutical Co., Ltd.

Dr. Hisafumi Okabe is the Senior Vice President, Office in charge of Research, Translational Clinical Research at Chugai Pharmaceutical Co. Ltd (Chugai). Dr. Okabe began his research career as a Postdoctoral Associate at Tokyo Metropolitan Institute of Medical Science and then at Yale University. He joined Nippon Roche Research Center in 1991 as a Research Scientist at the Department of Molecular Genetics and Department of Oncology & Mycology. After the merger of Nippon Roche and Chugai in 2002, he served as a Department Manager in the Pharmaceutical Research Department and later as a Department Manager in the Research Coordination and Planning Department. He also served as the head Research Division at Chugai. He was a Visiting Lecturer at the School of Medicine at Yokohama City University (1993-2002) and at the School of Medicine at Yamaguchi University. Dr. Hisafumi Okabe obtained his Ph.D. from Faculty of Science, Tohoku University in 1986.



Takeshi Yamamoto, PhD

Senior Manager
Pharmaceutical & Healthcare Research Laboratories
FujiFilm Corporation

With 13 years of experience in process development and scale-up technologies for photographic products at Fujifilm (1991-2004). With 8 years of experience as a technical manager and a project manager for photographic industry business at Fujifilm Manufacturing Europe B.V. (2004-2012). Since 2012, assigned for research and development of In-Vitro Diagnostics as a senior manager at Pharmaceutical & Healthcare Laboratories in Japan.



Tatsuo Mizuno

Executive Director and Secretary General
Malaria No More Japan

During his tenure at Sumitomo Chemical Co., Ltd from 2007 to 2012, he built overseas manufacturing base for and selling Olyset Net, award-winning LLIN (Long Lasting Insecticidal Nets), as well as establishing its research center for in Africa. Most notably, in Tanzania through manufacturing and sales of the product has created new employment of about 7,000 people. For this achievement, the success factors were: (1) firm commitment from both top managements and key managers; (2) appropriate selection of local partners followed by partnerships with them; (3) training local staff (tolerance for failure and comprehensive bottom-up approach); (4) quality management and control under through cost reductions.



Wataru Akahata, PhD

Founder & Chief Executive Officer
VLP Therapeutics

Dr. Wataru Akahata has extensive experience in vaccine development process ranging from basic discovery to applied sciences including clinical trials. He was a researcher at the Vaccine Research Center at the NIH and has over 10 years of experience in vaccine development against emerging infectious disease. He has developed virus-like particle (VLP) vaccines for Chikungunya virus and other five alphaviruses. Chikungunya virus vaccine is under Phase II clinical trial and his research efforts have led to several patents and peer reviewed publications. He also received the NIH Director's Award in the development of these alphavirus vaccines. In 2013, Dr. Akahata founded VLP Therapeutics to further pursue other vaccine development. The company based upon a novel, proprietary VLP technology, with the mission of developing innovative medical to address global unmet medical needs and to combat the 21st century global public health problems. VLP Therapeutics is dedicated to the development of next generation vaccines to fight infectious diseases, cancer and neurological diseases.

Session 4: Propelling R&D for Late-Stage Projects



Toshihiro Horii, PhD

Professor, Department of Molecular Protozoology
Research Institute for Microbial Diseases
Osaka University

He presently heads two research groups: the Department of Molecular Protozoology from 1999 and the Department of Infection Metagenomics from 2010, and served as Director for the Research Center for Infectious Disease Control from 2005 to 2016. He was also a Director of another




Jörg Möhrle, PhD

VP Head of Translational Medicine
Medicines for Malaria Venture (MMV)

Jörg J. Möhrle is VP Head of Translational Medicine at the Medicines for Malaria Venture (MMV). Jörg Möhrle joined MMV in 2005, and heads the translational medicine team which brings new drug candidates from the laboratory to Proof of Concept in patients, investigates combinations of new

special research facility, the International Research Center for Infectious Diseases from 2005 to 2016. His main interest is on malaria parasites and on the rapid identification of emerging and re-emerging infectious diseases. His laboratory has particularly undertaken novel studies on *Plasmodium falciparum* malaria vaccine development. He conducts clinical trials in two African countries: Uganda and Burkina Faso, both highly endemic areas for malaria for studies on the BK-SE36 vaccine development. Clinical trials for BK-SE36 are on going and his team will embark on a next-generation malaria vaccine for evaluation in adults to toddlers. Efficacy testing of the SE36 candidate is eagerly awaited by malaria vaccine research field.



Ford Von Reyn, MD

Professor,
Medicine, Infectious Disease and International Health
Director, DarDar International Programs at
Geisel School of Medicine

Dr. C. Fordham von Reyn ("Ford") is Professor of Medicine, Infectious Disease and International Health, and Director, DarDar International Programs at Geisel School of Medicine. He is a cum laude graduate of Harvard Medical School. He completed a Fellowship in Infectious Disease at Harvard then joined the Centers for Disease Control as State Epidemiologist for New Mexico working on plague and diphtheria. He began work on HIV in Africa as a consultant for the Special Program on AIDS of the World Health Organization before founding the Section of Infectious Disease and International Health at Geisel. Dr. von Reyn has been an NIH-funded investigator on TB and HIV for >20 years, including the DarDar Trial in Tanzania, the first successful efficacy trial of a new TB vaccine. He has been PI of the Dartmouth NIH Fogarty Training Grant with Tanzania since 2003. He has published over 100 manuscripts on HIV and TB, is a two-time recipient of the Geisel Clinical Faculty Teaching Award, a Lifetime Achievement Award from the International Union Against Tuberculosis, and an honorary Doctor of Science degree from Dartmouth College in 2017. He is leading the development of DAR-901, a TB booster vaccine, including a current Phase 2 trial among adolescents in Tanzania sponsored by GHIT.



Katsura Hata, D.V.M., PhD

Senior Director
Global Health Research Section,
hhc Data Creation Center, Eisai Co., Ltd.

Katsura HATA, a senior Director of Global Health Research Section, Eisai Co., Ltd.; received D. V. M. and Ph.D. from the University of Hokkaido with the research on development of a new azole antifungal; joined Eisai in 1988 and has worked in the infectious diseases fields; has engaged in the drug discovery of some new β -lactam antibiotics and antifungals, especially the new triazole antifungal, ravuconazole which is an active form of fosravuconazole; contributed to the development of APX001 (formally E1211), a novel antifungal with new mechanism of action (GWT1 inhibition), as a project leader; has studied in the field of malaria and neglected tropical diseases from 2009; is currently a project member of two programs for clinical development of fosravuconazole for Chagas disease and mycetoma in collaboration with DNDi, and two programs for anti-malarial drug discovery, a lead optimization study of a new GWT1 inhibitor and a hit to lead study, in collaboration with MMV funded by GHIT.

antimalarial compounds, undertakes pharmacometric analyses and modelling and develops new study designs to optimize the early drug development process. Before MMV he contributed to clinical development in the pharmaceutical and biotech industry across a range of indications, such as asthma, oncology, inflammatory diseases and neurology. Jörg studied biochemistry in Tübingen, Germany, received his MPhil in Cambridge, UK and obtained his PhD from Basel University, Switzerland for his work on protein kinases of *Plasmodium falciparum*. In October 2017, he obtained his habilitation and *venia docendi* in Infection Biology and Epidemiology from Basel University. Jörg also holds a MBA and is a fellow of the Institute of Clinical Research and a Chartered Scientist of the Science Council of the UK.



Remco de Vruh, PhD

Program Manager
Lygature

Remco de Vruh joined Lygature as Program manager in 2013, and is responsible for a small team that coordinates partnerships in the area of pharmaceutical R&D, including neglected tropical diseases. After he obtained his PhD in drug delivery in 1999, Remco worked at OctoPlus, a pharmaceutical SME, for almost seven years gaining extensive experience in running formulation development projects. From 2006 he fulfilled project management positions for a number of public bodies: the Dutch Steering Committee on Orphan Drugs, EDCTP, Netherlands Organisation for Health Research and Development and the Dutch Medicines Evaluation Board. From 2012 he worked as senior consultant for Schuttelaar & Partners a communication consultancy. Since the start of his professional career, Remco continues to perform scientific research in collaboration with various Dutch universities. He is the (co-)author of more than 30 scientific publications and book chapters. His current research focus is to better understand the process of Public and private engagement and the impact of pharmaceutical public-private partnerships on public health. Apart from research, he has (co-)organized numerous meetings, regularly provides presentations at conferences, and acts as guest lecturer.



Daisuke Imoto

Head of Office,
Drugs for Neglected Diseases *initiative* (DNDi) Japan

He leads the Japan Liaison Office of DNDi since May 2017, managing the partnership with different Japanese partners to bring Japanese expertise into the R&D portfolio of DNDi. He has more than 15 years of experience in the pharmaceutical industry and the international development with JBIC/JICA. He has an extensive experience in managing projects in multiple developing countries in different regions, notably Africa and MENA. B.S. from Faculty of Law, Tokyo University (2001); MBA from INSEAD (2012)

Session 5: Joining Forces for Product Delivery Preparedness



Masahiko Noda

Department of International Affairs,
Japan Agency for Medical Research and
Development (AMED)

Masahiko NODA is the Managing Director of the Department of International Affairs of Japan Agency for Medical Research and Development (AMED), which was launched on April 1st 2015. He previously joined the Preparatory office for launching AMED in 2014. Mr. NODA graduated from the Shinshu University, Graduate School of Science (M.Sc.). He joined the Research Development Corporation of Japan (JRDC) in 1982. He served as an official at the International Affairs Division of the Science and Technology Agency (STA) for two years from



Ole F. Olesen

Director of North-North Cooperation,
European and Developing Countries Clinical Trials
Partnership (EDCTP)

Dr Ole F. Olesen joined EDCTP in September 2013 as Director of North-North Cooperation. He studied at the universities of Aarhus, Denmark and Cambridge, UK, as well as at Copenhagen Business School. Dr Olesen holds a Masters and PhD degree in Molecular Biology and an HD degree in international economics. Dr Olesen has considerable work experience in conducting and managing large international projects on pharmaceutical product development. He also worked as assistant professor in pharmacology at Copenhagen University. Dr Olesen worked in the

1988. In 1990, he joined Japan Science and Technology Corporation (JST) and participated in the planning and launching of the National Museum of Emerging Science and Innovation (Miraikan), the Center for Research and Development Strategy (CRDS), and the Center for Low Carbon Society Strategy (LCS). He also served as a special staff at the Council for Science and Technology in 2000 and the Millennium project of Ministry of Education, Culture, Sports, science and Technology (MEXT) in 2001. In 2012, he joined the School of Engineering at the University of Tokyo in order to support the research management.

pharmaceutical industry for 10 years, initially as an international project manager and later in the position of Global Project Director. Before joining EDCTP, Dr Olesen was Principal Scientific Officer for Global Health at the European Commission's Directorate-General for Research & Innovation, where he was responsible for research in neglected infectious diseases and for vaccine research activities.




Sanne Fournier-Wendes

Senior Adviser to the Executive Director
Executive Office, UNITAID

Sanne FOURNIER-WENDES is the Senior Adviser to the Executive Director in UNITAID's Executive Office. A Danish national, sanne has over 15 years of experience in Strategy and Policy Development and partnership building and programme management. She worked in the Private Sector, the Global Fund and UN System. She holds a Bachelor's and a Master's in Economics. She has been at UTD for over 2 years.

Closing Remarks



BT Slingsby, MD, PhD, MPH

CEO
Global Health Innovative Technology Fund

Dr. Slingsby is CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund. Previously, he was the global head for access strategies at Eisai Co., Ltd. where he developed new business models for R&D and overlooked market access in the developing world. Dr. Slingsby has helped launch numerous start-ups in Japan and the U.S., and currently advises at the Graduate School of Medicine at the University of Tokyo and Kyoto University. He sits on the Public-Private Partnership Forum at the Institute of Medicine in the U.S., and has published over 50 peer-reviewed articles on medicine and public health in both Japanese and American literature. Dr. Slingsby graduated with honors from Brown University, earned Master's and Doctorate degrees from Kyoto University and the University of Tokyo, and received his Medical Doctorate from the George Washington University. He is a former professional triathlete and member of the U.S. World Cup Team.